Arcturus Therapeutics Ltd.(ARCT)

15.52-0.71-4.38%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT) and EyePoint Pharmaceuticals (EYPT)
  TIPRANKS · 12:30
  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT) and EyePoint Pharmaceuticals (EYPT)
- Arcturus Therapeutics to Present at H.C. Wainwright Global Investment Conference
  Reuters · 09-01 04:01
  Arcturus Therapeutics to Present at H.C. Wainwright Global Investment Conference
- Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)
  TIPRANKS · 08-26
  Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)
- Analysts Offer Insights on NA Companies: Arcturus Therapeutics (ARCT), EquipmentShare.com, Inc. (EQPT) and First Tracks Biotherapeutics Inc (TRAX)
  TIPRANKS · 08-20
  Analysts Offer Insights on NA Companies: Arcturus Therapeutics (ARCT), EquipmentShare.com, Inc. (EQPT) and First Tracks Biotherapeutics Inc (TRAX)
- Analysts’ Opinions Are Mixed on These NA Stocks: Cardinal Infrastructure Group, Inc. (CDNL), Arcturus Therapeutics (ARCT) and Ceribell, Inc. (CBLL)
  TIPRANKS · 08-11
  Analysts’ Opinions Are Mixed on These NA Stocks: Cardinal Infrastructure Group, Inc. (CDNL), Arcturus Therapeutics (ARCT) and Ceribell, Inc. (CBLL)
- Arcturus Therapeutics Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
  Reuters · 08-07
  Arcturus Therapeutics Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
- Arcturus Q2 Revenue Falls Sharply on CSL Seqirus Deal End
  Reuters · 08-07
  Arcturus Q2 Revenue Falls Sharply on CSL Seqirus Deal End
- Arcturus Therapeutics Q2 Net Income USD -23.785 Million
  Reuters · 08-07
  Arcturus Therapeutics Q2 Net Income USD -23.785 Million
- Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
  THOMSON REUTERS · 08-07
  Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress
- Arcturus Therapeutics Holdings Inc Expected to Post a Loss of 100 Cents a Share - Earnings Preview
  Reuters · 08-05
  Arcturus Therapeutics Holdings Inc Expected to Post a Loss of 100 Cents a Share - Earnings Preview
- Arcturus Therapeutics Updates Financial Calendar with Upcoming Q2 Results Release and Conference Call
  Reuters · 07-29
  Arcturus Therapeutics Updates Financial Calendar with Upcoming Q2 Results Release and Conference Call
- Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
  THOMSON REUTERS · 07-29
  Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026
- Arcturus Therapeutics to Present at the Canaccord Genuity 46TH Annual Growth Conference
  THOMSON REUTERS · 07-21
  Arcturus Therapeutics to Present at the Canaccord Genuity 46TH Annual Growth Conference
- Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Arcturus Therapeutics (ARCT)
  TIPRANKS · 07-15
  Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Arcturus Therapeutics (ARCT)
- U.S. Stocks on the Move-silicom, Blue Owl, Intel
  Reuters · 07-03
  U.S. Stocks on the Move-silicom, Blue Owl, Intel
- Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (FTH) and Arcturus Therapeutics (ARCT)
  TIPRANKS · 07-03
  Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (FTH) and Arcturus Therapeutics (ARCT)
- Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth
  TIPRANKS · 07-02
  Arcturus, Thermo Fisher deal adds support to ARCT-032 exposure, says Roth
- U.S. Stocks on the MOVE- Dollar Tree, Rivian, Arcturus
  Reuters · 07-02
  U.S. Stocks on the MOVE- Dollar Tree, Rivian, Arcturus
- Arcturus Rises on Thermo Fisher Collaboration for Rare Disease Drug
  Reuters · 07-02
  Arcturus Rises on Thermo Fisher Collaboration for Rare Disease Drug
- Arcturus Therapeutics Partners with Thermo Fisher to Support Phase 3 Development of Cystic Fibrosis Therapy Arct-032
  Reuters · 07-02
  Arcturus Therapeutics Partners with Thermo Fisher to Support Phase 3 Development of Cystic Fibrosis Therapy Arct-032
Company Profile
Company Name
Arcturus Therapeutics Ltd.
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.arcturusrx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
- 08-25
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 08-07
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 08-07
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 07-02
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 06-05
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-07
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 05-07
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 05-07
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 03-03
  Annual Report
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
  Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
- 03-03
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-12-15
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-11-12
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 2025-11-10
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-10-22
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 2025-09-26
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report

1D
5D
Day
Week
Month

Loading ...

High

17.75

Open

16.46

Volume%

1.30

Low

15.46

16.23

T/O Rate

2.54%

To The Moon

Arcturus Therapeutics Ltd.(ARCT)

Company Profile

Most Discussed